W
Withus Pharmaceutical Co Ltd
KOSDAQ:330350
Withus Pharmaceutical Co Ltd
KOSDAQ:330350
Price:
9 190
KRW
-1.61%
Market Cap:
₩121.3B
Balance Sheet
Balance Sheet Decomposition
Withus Pharmaceutical Co Ltd
Withus Pharmaceutical Co Ltd
Balance Sheet Decomposition is not available for
Withus Pharmaceutical Co Ltd
Withus Pharmaceutical Co Ltd
Balance Sheet
Withus Pharmaceutical Co Ltd
Withus Pharmaceutical Co Ltd
Currency: KRW
| Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & Cash Equivalents |
15 490
|
13 831
|
9 012
|
9 173
|
17 893
|
|
| Cash |
1
|
1
|
1
|
0
|
1
|
|
| Cash Equivalents |
15 489
|
13 830
|
9 011
|
9 173
|
17 893
|
|
| Short-Term Investments |
23 944
|
28 647
|
17 544
|
2 019
|
1 000
|
|
| Total Receivables |
26 625
|
24 228
|
23 372
|
30 978
|
26 099
|
|
| Accounts Receivables |
20 487
|
18 714
|
17 896
|
25 839
|
22 141
|
|
| Other Receivables |
6 138
|
5 514
|
5 475
|
5 139
|
3 957
|
|
| Inventory |
7 922
|
8 141
|
9 021
|
16 004
|
16 151
|
|
| Other Current Assets |
33
|
1 581
|
501
|
73
|
29
|
|
| Total Current Assets |
74 015
|
76 427
|
59 451
|
58 247
|
61 173
|
|
| PP&E Net |
20 071
|
25 379
|
39 843
|
49 945
|
49 236
|
|
| PP&E Gross |
20 071
|
25 379
|
39 843
|
49 945
|
49 236
|
|
| Accumulated Depreciation |
9 790
|
10 947
|
11 571
|
12 783
|
15 218
|
|
| Intangible Assets |
2 950
|
6 583
|
8 421
|
8 847
|
10 839
|
|
| Note Receivable |
471
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
7 209
|
8 733
|
9 637
|
12 099
|
11 881
|
|
| Other Long-Term Assets |
1 463
|
1 856
|
2 043
|
1 642
|
1 559
|
|
| Total Assets |
106 180
N/A
|
118 979
+12%
|
119 395
+0%
|
130 780
+10%
|
134 687
+3%
|
|
| Liabilities | ||||||
| Accounts Payable |
5 829
|
7 486
|
8 558
|
14 315
|
3 620
|
|
| Accrued Liabilities |
740
|
525
|
244
|
49
|
1 781
|
|
| Short-Term Debt |
10 589
|
12 839
|
12 519
|
11 424
|
19 000
|
|
| Current Portion of Long-Term Debt |
2 203
|
1 280
|
2 172
|
3 535
|
2 505
|
|
| Other Current Liabilities |
987
|
1 845
|
2 080
|
1 688
|
7 032
|
|
| Total Current Liabilities |
20 349
|
23 975
|
25 572
|
31 011
|
33 938
|
|
| Long-Term Debt |
4 427
|
8 986
|
6 776
|
5 042
|
2 560
|
|
| Other Liabilities |
4 527
|
5 113
|
4 011
|
4 449
|
5 073
|
|
| Total Liabilities |
29 303
N/A
|
38 074
+30%
|
36 359
-5%
|
40 502
+11%
|
41 571
+3%
|
|
| Equity | ||||||
| Common Stock |
1 758
|
2 638
|
2 639
|
2 640
|
2 640
|
|
| Retained Earnings |
58 880
|
62 642
|
64 736
|
71 894
|
74 733
|
|
| Additional Paid In Capital |
16 239
|
14 948
|
14 997
|
15 109
|
15 109
|
|
| Treasury Stock |
0
|
0
|
36
|
36
|
36
|
|
| Other Equity |
0
|
678
|
700
|
671
|
671
|
|
| Total Equity |
76 877
N/A
|
80 905
+5%
|
83 036
+3%
|
90 278
+9%
|
93 117
+3%
|
|
| Total Liabilities & Equity |
106 180
N/A
|
118 979
+12%
|
119 395
+0%
|
130 780
+10%
|
134 687
+3%
|
|
| Shares Outstanding | ||||||
| Common Shares Outstanding |
9
|
13
|
13
|
13
|
13
|
|
Switch to:
Switch to:
See Also
Discover More
